Silymarin nanoemulsion against human hepatocellular carcinoma: development and optimization
Source abstract
Abstract
Objective Nanoemulsion of silymarin was developed and optimized. Materials and methods Nanoemulsion was made by aqueous titration method. Sefsol 218 (5.8% v/v), Kolliphor RH40 and polyethylene glycol 400 (Smix; 2:1; 28.99% v/v) were used as oil phase, surfactant and co-surfactant while distilled water (65.22% v/v) acted as an aqueous phase. Nanoemulsion was characterized on the basis of particle size, viscosity, electrical conductivity and refractive index. Further, in vitro release, in vivo pharmacokinetic study, stability study and cancer cell line studies were also performed. Results and discussion The optimized formulation (NE9) with mean particle size of 21.24 nm showed a minimum viscosity of 9.59 cps, maximum drug release (97.75%) in 24 h. The NE9 formulation also showed higher AUC (p < .01) and Cmax (p < .01) and shorter Tmax (p < .05) compared with conventional and standard suspensions of silymarin. The stability study also showed considerably stable formulations at refrigerator temperature as compared with room temperature (p > .05). The cancer cell line studies also confirmed that silymarin nanoemulsion reduced the cell viability and increased ROS intensity and chromatin condensation (p < .05). Conclusion Our results concluded that nanoemulsion may be an efficient carrier for oral delivery of silymarin against human hepatocellular carcinoma without damaging normal cells.
Source: europepmc · Quality: candidate unverified · Source record ↗
Research context
OpenAlex topics: Silymarin and Mushroom Poisoning · Pharmacological Effects of Natural Compounds · Curcumin's Biomedical Applications
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Department of Pharmaceutics, Faculty of Pharmacy, Integral University, Lucknow, India;
Department of Pharmaceutics, Faculty of Pharmacy, Jamia Hamdard, New Delhi, India;
Molecular Endocrinology Laboratory, Department of Zoology, University of Lucknow, Lucknow, India;
Department of Pharmacokinetics, Central Drug Research Institute, Lucknow, India
References (43)
Show source-provided references
1. 10.1016/j.indcrop.2011.03.02710.1016/j.indcrop.2011.03.027 ↗
2. 10.1016/j.jep.2007.10.02410.1016/j.jep.2007.10.024 ↗
3. 10.3390/molecules1411430010.3390/molecules14114300 ↗
4. 10.4103/0253-7613.3653410.4103/0253-7613.36534 ↗
5. 10.1007/s11738-015-2008-310.1007/s11738-015-2008-3 ↗
6. Javed S · Altern Med Rev · 2011 · 16 · 239
7. 10.1021/nl102184c10.1021/nl102184c ↗
8. 10.1038/nbt1006-121110.1038/nbt1006-1211 ↗
9. 10.1002/app.2745010.1002/app.27450 ↗
10. 10.1007/978-1-61779-983-910.1007/978-1-61779-983-9 ↗
11. 10.1002/jps.260082100810.1002/jps.2600821008 ↗
12. 10.1002/(SICI)1099-081X(199711)18:8<737::AID-BDD59>3.0.CO;2-910.1002/(SICI)1099-081X(199711)18:8<737::AID-BDD59>3.0.CO;2-9 ↗
13. 10.1002/jps.260077051210.1002/jps.2600770512 ↗
14. 10.1021/js980403l10.1021/js980403l ↗
15. Aungst BJ · BT Gattefosse · 1994 · 87 · 49
16. 10.1248/cpb.38.280110.1248/cpb.38.2801 ↗
17. 10.1016/j.ejpb.2005.12.00510.1016/j.ejpb.2005.12.005 ↗
18. 10.1002/jps.260067101110.1002/jps.2600671011 ↗
19. 10.1023/A:101589673154510.1023/A:1015896731545 ↗
20. 10.1016/0378-5173(92)90374-B10.1016/0378-5173(92)90374-B ↗
21. 10.1016/0378-5173(86)90043-810.1016/0378-5173(86)90043-8 ↗
22. 10.1016/S0169-409X(00)00103-410.1016/S0169-409X(00)00103-4 ↗
23. 10.3109/10717544.2015.107729010.3109/10717544.2015.1077290 ↗
24. 10.2174/15672010677773111810.2174/156720106777731118 ↗
25. 10.1007/BF0120911910.1007/BF01209119 ↗
26. 10.1208/pt080202810.1208/pt0802028 ↗
27. 10.1016/S0169-409X(01)00105-310.1016/S0169-409X(01)00105-3 ↗
28. 10.1016/j.ejpb.2006.10.01410.1016/j.ejpb.2006.10.014 ↗
29. 10.1016/S0378-5173(00)00614-110.1016/S0378-5173(00)00614-1 ↗
30. Akhtar J.
31. Parveen R · Biomed Chromatogr · 2010 · 24 · 63910.1002/bmc.1340 ↗
32. 10.2174/15672018110214041116081710.2174/156720181102140411160817 ↗
33. Fraga M · Die Pharmazie-Int J Pharm Sci · 2008 · 63 · 667
34. 10.1111/cpr.1219510.1111/cpr.12195 ↗
35. 10.1002/cbin.1055210.1002/cbin.10552 ↗
36. 10.1016/j.ijpharm.2011.04.04110.1016/j.ijpharm.2011.04.041 ↗
37. 10.1016/j.lwt.2015.03.09110.1016/j.lwt.2015.03.091 ↗
38. 10.1016/j.mrgentox.2015.08.00610.1016/j.mrgentox.2015.08.006 ↗
39. 10.1007/BF0297778210.1007/BF02977782 ↗
40. 10.1016/j.pharep.2014.04.00710.1016/j.pharep.2014.04.007 ↗
41. 10.1111/j.1365-2184.2008.00581.x10.1111/j.1365-2184.2008.00581.x ↗
42. 10.1016/S0300-9084(02)01369-X10.1016/S0300-9084(02)01369-X ↗
43. 10.1007/s13277-011-0288-910.1007/s13277-011-0288-9 ↗